- Home
- EDN vs SVRA Comparison
EDN vs SVRA Comparison
Compare EDN & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$4.22
Company Overview
Basic Information| Metric | EDN | SVRA |
|---|---|---|
| Founded | 1992 | 2007 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2007 | 2009 |
Fundamental Metrics
Financial Performance| Metric | EDN | SVRA |
|---|---|---|
| Price | $18.88 | $4.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $38.50 | $11.06 |
| AVG Volume (30 Days) | 165.4K | ★ 2.5M |
| Earning Date | 08-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.13 | N/A |
| Revenue Next Year | $22.69 | $4,406.08 |
| P/E Ratio | $16.98 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.12 | $3.86 |
| 52 Week High | $36.70 | $7.01 |
Technical Indicators
Market Signals| Indicator | EDN | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 30.37 | 30.21 |
| Support Level | N/A | N/A |
| Resistance Level | $21.01 | $5.53 |
| Average True Range (ATR) | 0.78 | 0.27 |
| MACD | -0.08 | -0.03 |
| Stochastic Oscillator | 18.66 | 5.43 |
Price Performance
Historical Comparison EDN
SVRA
About EDN Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)
Empresa Distribuidora y Comercializadora Norte SA is engaged in the distribution and sale of electricity. The firm's concession area covers the northern portion of the city of Buenos Aires, mainly for residential, commercial, industrial, and public service.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).